NCI Navigant Consulting Inc.

Navigant Life Sciences Leader Named Consulting Magazine “Rising Star”

Navigant (NYSE:NCI) today announced that Elena Stavrakas, a director in the firm’s Healthcare Life Sciences practice, has been recognized among the 2017 “Rising Stars of the Profession” by ALM’s Consulting magazine. Stavrakas was selected from more than 200 nominees considered for the recognition, an annual list honoring 35 young up-and-comers in the consulting profession under the age of 35.

“The ‘Rising Stars of the Profession’ award isn’t just about talent and potential, it’s about results and impact,” said Consulting Editor & Publisher Joe Kornik. “These 35 winners are difference makers to their firms, co-workers and their clients, but they’re also moving the needle for the entire consulting profession. And all before their 35th birthdays; it’s simply amazing.”

Stavrakas, 33, specializes in biopharmaceutical strategic commercial advisory with a particular focus on rare diseases, commercial launch excellence, and business development strategy. Since joining Navigant in 2008, she has overseen partnerships with some of the industry’s leading pharmaceutical companies, supporting delivery of complex disease area strategies, on-site brand planning and execution, prioritization of acquisition opportunities, and forecast model design and implementation.

“Elena has helped to build Navigant’s Life Sciences group into a vibrant practice,” said David Zito, Navigant managing director and healthcare segment leader. “Her ability to develop relationships both internally and with key senior-level clients enables Navigant’s Life Sciences practice to support a wide range of successful initiatives, from pre-launch to post-launch.”

Stavrakas also co-leads Navigant Life Sciences’ new hire training, helping to shape professionals for successful life sciences careers. A graduate of Haverford College in Haverford, Pa., she began her career in healthcare investment banking before transitioning into consulting.

“I’m fortunate to be part of a team that collaborates with biotech and pharmaceutical industry leadership to develop products and services that impact people’s lives,” said Stavrakas. “It is truly an honor to receive this recognition, which further validates the exceptional value and partnership our team provides to our clients.”

The “Rising Stars of the Profession” are recognized for excellence in the following areas: leadership, client service, strategy consulting, operations management consulting, healthcare, financial services, high tech, retail, information technology, and human resources.

This year’s honorees will be recognized by Consulting magazine at a gala awards dinner at the W Chicago City Center on Thursday, April 27.

Stavrakas’ full profile appears in the March 2017 issue of Consulting magazine.

About Navigant

Navigant Consulting, Inc. (NYSE: NCI) is a specialized, global professional services firm that helps clients take control of their future. Navigant’s professionals apply deep industry knowledge, substantive technical expertise, and an enterprising approach to help clients build, manage, and/or protect their business interests. With a focus on markets and clients facing transformational change and significant regulatory or legal pressures, the firm primarily serves clients in the healthcare, energy, and financial services industries. Across a range of advisory, consulting, outsourcing, and technology/analytics services, Navigant’s practitioners bring sharp insight that pinpoints opportunities and delivers powerful results. More information about Navigant can be found at navigant.com.

EN
13/03/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Navigant Consulting Inc.

NAVIGANT CNSL.INCO. is slightly downgraded to Slightly Positive due to...

The independent financial analyst theScreener just slightly lowered the general evaluation of NAVIGANT CNSL.INCO. (US), active in the Business Support Services industry. As regards its fundamental valuation, the title confirms its rating of 3 out of 4 stars while its market behaviour remains unchanged and can be qualified as defensive. However, a marginally less favourable environment forces theScreener to downgrade slightly the title, which now shows an overall rating of Slightly Positive. As o...

Valens Research
  • Valens Research

Valens Equity Insights and Inflections - 2019 04 17

BZH currently trades near recent lows relative to UAFRS-based (Uniform) Earnings, with a 6.7x Uniform P/E. At these levels, the market is pricing in expectations for Uniform ROA to decline from 11% in 2018 to 5% in 2023, accompanied by 1% Uniform Asset growth going forward. However, analysts have bullish expectations, projecting Uniform ROA to expand to 13% through 2020, accompanied by 3% Uniform Asset shrinkage. Moreover, management is confident in structural plan options, their balanced growth...

Valens Research
  • Valens Research

NCI - Embedded Expectations Analysis - 2019 04 11

Navigant Consulting Inc. (NCI:USA) currently trades below recent averages relative to UAFRS-based (Uniform) Earnings, with a 15.6x Uniform P/E. Even at these levels, the market is pricing in expectations for Uniform ROA to improve from a low of 9% in 2018 to 11% in 2023. Specifically, markets appear optimistic about the competitive position of the firm's remaining industry segments and the potential to drive top-line growth. However, they may be skeptical of the benefits of a simplified portfol...

MarketLine Department
  • MarketLine Department

ICF International, Inc. - Mergers & Acquisitions (M&A), Partnerships &...

Summary Marketline's ICF International, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by ICF International, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of th...

2 directors sold after exercising options/sold

Two Directors at Navigant Consulting Inc sold after exercising options/sold 49,598 shares at between 24.120USD and 24.240USD. The significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch